Back to search
FDAFDA · Food and drugs·Recall number D-1614-2020

WP Thyroid, Westhroid Pure, 1/2 Grain (32.5 mg) Thyroid USP [Liothyronine (T3) 4.5 mcg, Levothyroxine (T4) 19 mcg], packaged in a) 30-count bottles (NDC 64727-5550-4), b) 90-count bottles (NDC 64727-5550-6), c) 100-count bottles (NDC 64727-5550-1), Rx only, Manufactured by: RLC Labs Phoenix, AZ 85024

Published September 23, 2020 · Recall initiated: August 25, 2020

Summary

FDA records drug Class I recall D-1614-2020, published September 23, 2020 and initiated August 25, 2020. Recalling firm: RLC Labs Inc.; Status: Terminated; Reported quantity: N/A; Lot: Lot #: 119142, Exp. Date 01/2022. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent Drug: FDA analysis found product to be subpotent

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
RLC Labs Inc.
Distributor
Nationwide in the United States
Lot
Lot #: 119142, Exp. Date 01/2022
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was WP Thyroid, Westhroid Pure, 1/2 Grain (32.5 mg) Thyroid USP [Liothyronine (T3) 4.5 mcg, Levothyroxine (T4) 19 mcg], packaged in a) 30-count bottles (NDC 64727-5550-4), b) 90-count bottles (NDC 64727-5550-6), c) 100-count bottles (NDC 64727-5550-1), Rx only, Manufactured by: RLC Labs Phoenix, AZ 85024 recalled?

Yes. FDA published recall D-1614-2020 on September 23, 2020. Reported hazard: Subpotent Drug: FDA analysis found product to be subpotent

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail